Correlation of MR-Based Metabolomics and Molecular Profiling in the Tumor Microenvironment of Temozolomide-Treated Orthotopic GL261 Glioblastoma in Mice
International Journal of Molecular Sciences · 18.12.2023 · 24 (24) · 17628
DOI: 10.3390/ijms242417628 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 18.12.2023. Verfasst von Kai Zhao und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Philipps University Marburg, Baldingerstrasse, 35043 Marburg, Germany. Hauptthemen laut MEDLINE: Glioblastoma, Glioma. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Centro de Investigación Biomédica en Red-Bioingeniería, Biomateriales y Nanomedicina, Federal Ministry of Education and Research (BMBF) Germany, Universitätsklinikum Gießen und Marburg.
Abstract (Originalsprache)
The tumor microenvironment in glioblastoma (GB) is considered to be “cold”, i.e., the fraction of cytotoxic T cells, for instance, is low. Instead, macrophages are the major immune cell population in GB, which stem either from tissue response (resident microglia) or recruitment of macrophages from the periphery, thereby undergoing tumor-dependent “imprinting” mechanisms by which macrophages can adapt a tumor-supportive phenotype. In this regard, it is important to describe the nature of macrophages associated with GB, in particular under therapy conditions using the gold standard chemotherapy drug temozolomide (TMZ). Here, we explored the suitability of combining information from in vivo magnetic resonance spectroscopic (MRS) approaches (metabolomics) with in vitro molecular analyses to assess therapy response and characterize macrophage populations in mouse GB using an isogenic GL261 model. For macrophage profiling, expression levels of matrix metalloproteinases (MMPs) and A disintegrin and metalloproteinases (ADAMs) were determined, since their gene products affect macrophage–tumor cell communication by extensive cleavage of immunomodulatory membrane proteins, such as PD-L1. In tumor mice with an overall therapy response, expression of genes encoding the proteases ADAM8, ADAM10, and ADAM17 was increased and might contribute to the immunosuppressive phenotype of GB and immune cells. In tumors responding to therapy, expression levels of ADAM8 were upregulated by TMZ, and higher levels of PD-L1 were correlated significantly. Using a CRISPR/Cas9 knockout of ADAM8 in GL261 cells, we demonstrated that soluble PD-L1 (sPD-L1) is only generated in the presence of ADAM8. Moreover, primary macrophages from WT and ADAM8-deficient mice showed ADAM8-dependent release of sPD-L1, independent of the macrophage polarization state. Since ADAM8 expression is induced in responding tumors and PD-L1 shedding is likely to decrease the anti-tumor activities of T-cells, we conclude that immunotherapy resistance is caused, at least in part, by the increased presence of proteases, such as ADAM8.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosurgery, Philipps University Marburg, Baldingerstrasse, 35043 Marburg, Germany.
- Departament de Bioquímica i Biologia Molecular, Facultat de Biociències, Universitat Autònoma de Barcelona, 08193 Cerdanyola del Vallès, Spain.
- Centro de Investigación Biomédica en Red: Bioingeniería, Biomateriales y Nanomedicina, 08193 Cerdanyola del Vallès, Spain.
- Center for Mind, Brain and Behavior (CMBB), Hans-Meerwein-Strasse 6, 35032 Marburg, Germany.
- Department of Neuropathology, Philipps University Marburg, Baldingerstrasse, 35043 Marburg, Germany.
- Department of Neuropathology, Core Facility Mouse Pathology and Electron Microscopy, Philipps-University Marburg, 35037 Marburg, Germany.
ORCID-Profile: Kai Zhao, Pilar Calero-Pérez, Miriam H A Bopp, Axel Pagenstecher, Marta Mulero-Acevedo, Carlos Barcia, Carles Arús, Christopher Nimsky, Tillmann Rusch, Jörg W Bartsch, Ana Paula Candiota
Förderung
- Centro de Investigación Biomédica en Red-Bioingeniería, Biomateriales y Nanomedicina
- Federal Ministry of Education and Research (BMBF) Germany
- Universitätsklinikum Gießen und Marburg
- PID2020-113058GB-I00
- PID2021-128717OB-I00
- MCIN/AEI/10.13039/501100011033
- Chinese Scholarship Council (CSC), J.W.B. by the ERANET PerMed research grant, project “PerProGlio”
- University Medical Center Giessen and Marburg
Zitieren
APA
Zhao, K., Calero-Pérez, P., Bopp, M. H. A., Möschl, V., Pagenstecher, A., Mulero-Acevedo, M., Vázquez, M., Barcia, C., Arús, C., Nimsky, C., Rusch, T., Bartsch, J. W., & Candiota, A. P. (2023). Correlation of MR-Based Metabolomics and Molecular Profiling in the Tumor Microenvironment of Temozolomide-Treated Orthotopic GL261 Glioblastoma in Mice. International Journal of Molecular Sciences, 24(24), 17628. https://doi.org/10.3390/ijms242417628
Vancouver
Zhao K, Calero-Pérez P, Bopp MHA, Möschl V, Pagenstecher A, Mulero-Acevedo M, et al. Correlation of MR-Based Metabolomics and Molecular Profiling in the Tumor Microenvironment of Temozolomide-Treated Orthotopic GL261 Glioblastoma in Mice. International Journal of Molecular Sciences. 2023;24(24):17628. doi:10.3390/ijms242417628
BibTeX
@article{Zhao2023,
author = {Zhao, Kai and Calero-Pérez, Pilar and Bopp, Miriam H A and Möschl, Vincent and Pagenstecher, Axel and Mulero-Acevedo, Marta and Vázquez, Mario and Barcia, Carlos and Arús, Carles and Nimsky, Christopher and Rusch, Tillmann and Bartsch, Jörg W and Candiota, Ana Paula},
title = {Correlation of MR-Based Metabolomics and Molecular Profiling in the Tumor Microenvironment of Temozolomide-Treated Orthotopic GL261 Glioblastoma in Mice},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {24},
pages = {17628},
doi = {10.3390/ijms242417628}
}
EUVIMED